期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

克唑替尼治疗ALK阳性非小细胞肺癌脑转移的疗效观察 被引量：7

Efficacy analysis of crizotinib for brain metastases in ALK-rearrangement-positive non-small cell lung cancer
下载PDF
导出
摘要 背景与目的:克唑替尼对间变性淋巴瘤激酶(anaplastic lymphoma kinase,ALK)阳性非小细胞肺癌(non-small cell lung cancer,NSCLC)具有显著疗效,但在治疗中往往出现脑转移,本研究旨在探讨克唑替尼在ALK阳性NSCLC脑转移患者中的治疗疗效和治疗模式。方法:对2011年1月—2014年8月在解放军八一医院接受克唑替尼治疗的6例ALK阳性NSCLC脑转移患者的临床资料进行回顾性分析。结果:3例克唑替尼治疗前基线有脑转移患者,颅内疗效部分缓解(partial response,PR)1例、疾病稳定(stable disease,SD)2例;第1次服用克唑替尼治疗至第1次出现疾病进展(progressive disease,PD)的中位时间为5.7个月,且第1次疾病进展的部位均为脑。6例患者脑病灶进展接受放疗后继续服用克唑替尼治疗,中位无进展生存期(progression free survival,PFS)为4.0个月,其中1例患者继续接受克唑替尼治疗的PFS达23.3个月,颅内病灶疗效完全缓解(complete response,CR)。结论:克唑替尼治疗ALK阳性NSCLC脑转移患者有效,且对于单纯颅内病灶进展放疗后,继续接受克唑替尼治疗仍然有效,是临床上可以选择的治疗方式。 Background and purpose： Although crizotinib could manifest marked antitumor activity in anaplastic lymphoma kinase（ALK）-rearrangement-positive non-small cell lung cancer（NSCLC） patients, but brain metastases is always occured in such patients. This study aimed to explore the effi cacy and treatment mode of crizotinib for brain metastases in ALK-rearrangement-positive NSCLC. Methods： The clinical data of 6 patients with brain metastases in ALK-rearrangement-positive NSCLC treated in 81 Hospital of PLA from Jan. 2011 to Aug. 2014 were analyzed retrospectively. Results： Three patients had brain metastases before crizotinib administration, 1 obtained partial response（PR） and 2 obtained stable disease（SD） in intracraninal tumors. The median progression free survival（PFS）for the fi rst period of crizotinib administration were 5.7 months, and the sites of fi rst disease progression were brains. All the 6 patients continued to receive crizotinib after radiotherapy with the median PFS of 4 months. One patient even experienced a median PFS of 23.3 months for the second period of crizotinib administration, and her brain tumors obtained complete response（CR）. Conclusion： The data of this study suggest that crizotinib is effective for brain metastases in ALK-rearrangement-positive NSCLC, and continued administration of crizotinib after radiotherapy for isolated intracraninal tumor progression is a elective treatment option for such patients.
作者 黄伟 王琳 秦叔逵 杨宁蓉 李嵘 寻琛 夏兆君
机构地区 解放军八一医院全军肿瘤中心肿瘤内科
出处 《中国癌症杂志》 CAS CSCD 北大核心 2015年第6期468-472,共5页 China Oncology
关键词 非小细胞肺癌 脑转移 间变性淋巴瘤激酶 克唑替尼 Non-small cell lung cancer Brain metastases Anaplastic lymphoma kinase Crizotinib
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献16

  • 1HEON S, YEAP B Y, BRITT G J, et al. Development of central nervous systerm metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib [ J ] . Clin Cancer Res, 2010, 16(23): 5873-82.
  • 2CAMIDGE D R, BANG Y J, KWAK E L, et al. Activity and safety of crizotinib in patients with ALK-positive non-small- cell lung cancer: updated results from a phase 1 study [ J ] . Lancet Oncol, 2012, 13: 1011-1019.
  • 3CHUN S G, CHOE K S, IYENGAR P, et aL Isolated central nervous system progression on Crizotinib: an Achilles heel of non-smal|-ce|l lung cancer with EML4-ALK trans|ocation? [ J ] . Cancer Biol Ther, 2012, 13(14): 1376-1383.
  • 4SHAW A T, KIM D W, NAKAGAWA K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer [ J - . N Engl J Med, 2013, 368: 2385-2394.
  • 5COSTA D B, KOBAYASHI S, PANDYA S S, et al. CSF concentration of the anaplastie lymphoma kinase inhibitor crizotinib [ J - . J Clin Oncol, 2011, 29: e443-e445.
  • 6KANEDA H, OKAMOTO I, NAKAGAWA K. Rapid response of brain metastasis to crizotinb in a patient with ALK rearrangement-positive non-small-cell lung cancer [ J ] . J Thorac Oncol, 2013, 8(4): e32-e33.
  • 7KINOSHITA Y, KOGA Y, SAKAMOTO A, et al. Long-lasting response to crizotinb in brain metastases due to EMIA-ALK- rearranged non-small-cell lung cancer [ J ] . BMJ Case Rep, 2013. doi: 10.1136/bcr-2013-200867.
  • 8WEICKHARDT A J, SCHEIER B, BURKE J M, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer [ J ] . J Thorac Oncol, 2012, 7: 1807-1814.
  • 9MAILLET D, MARTEL L I, ARPIN D, et al. Ineffectiveness of crizotinib on brain metastases in two cases of lung adenocarcinoma with EML4-ALK rearrangement [ J ] . J Thorac Oncol, 2013, 8:e30-e31.
  • 10SHUKUYA T, TAKAHASHI T, NAITO T, et al. Continuous EGFR-TKI administration following radiotherapy for non- small cell lung cancer patients with isolated CNS failure [ J ] . Lung Cancer, 2011, 74: 457-461.

同被引文献76

  • 1Nayak L, Lee EqWen PY. Epidemiology of brain metastases[J]. Curt Oncol Rep, 2012, 14(1): 48-54.
  • 2Olmez I, Donahue BR, Butler JS, et al. Clinical outcomes in extracranial tumor sites and unusual toxicities with concurrent whole brain radiation (WBRT) and Erlotinib treatment in patients with non-small cell lung cancer (NSCLC) with brain metastasis[J]. Lung Cancer, 2010, 70(2): 174-179.
  • 3Sajama C, Lorenzoni J, Tagle P. Diagnosis and treatment of brain metastasis[J]. Rev Med Chil, 2008, 136(10): 1321-1326.
  • 4Sinchez de Cos J, Sojo Gonz:ilez MA, Montero MV, et al. Non-smaU cell lung cancer and silent brain metastasis. Survival and prognostic factors [J]. Lung Cancer, 2009, 63 (1): 140-145.
  • 5Tabouret E, Chinot O, Metellus P, et al. Recent trends in epidemiology of brain metastases: an overview[J]. Anticancer Res, 2012, 32(1 i): 4655-4662.
  • 6Smedby KE, Brandt L, Bicklund ML, et al. Brain metastases admissions in Sweden between 1987 and 2006[J]. BrJ Cancer, 2009, 101(11): 1919-1924.
  • 7Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer[J]. Nature, 2007, 448(7153): 561-566.
  • 8Saha A, Pandian GN, Sato S, et al. Synthesis and biological evaluation of a targeted DNA-binding transcriptional activator with HDAC8 inhibitory activity I J]. Bioorg Med Chem, 2013, 21 ( 14): 4201-4209.
  • 9Pont LM, Naipal K, Kloezeman JJ, et al. DNA damage response and anti-apoptotic proteins predict radiosensitization efficacy of HDAC inhibitors SAHA and LBH589 in patient-derived glioblastoma cells[J]. Cancer Lett, 2015, 356(2 Pt B): 525-535.
  • 10Kriiger S, Meier C. Synthesis of Site-Specific Damaged DNA Strands by 8-(Acetylarylamino)-2'-deoxyguanosine Adducts and Effects on Various DNA Polymerases[J]. European J Org Chem, 2013, 2013(6): 1158-1169.

引证文献7

二级引证文献39

中国癌症杂志
2015年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部